Discover
NKTR
Nektar Therapeutics
67.10
1 x 57.62
1 x 76.66
bid
ask
-
1.26
1.84%
1 @ 04:16 AM
67.50 +0.40 (0.60%)
| Ytd | 58.70% | |
| 1y | 14.19% |
66.98
day range
69.09
33.40
52 week range
109.00
| Open | 68.00 | Prev Close | 68.36 | Low | 66.98 | High | 69.09 | Mkt Cap | 2.29B |
| Vol | 2.81M | Avg Vol | 902.77K | EPS | -6.12 | P/E | N/A | Forward P/E | -6.19 |
| Beta | 1.15 | Short Ratio | 10.71 | Inst. Own | 106.44% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 71.66 | 200-d Avg | 65.35 | 1yr Est | 144.40 |
NKTR News
defenseworld.net
Analyzing Nektar Therapeutics (NASDAQ:NKTR) & Evaxion A/S (NASDAQ:EVAX)
Evaxion A/S (NASDAQ: EVAX - Get Free Report) and Nektar Therapeutics (NASDAQ: NKTR - Get Free Report
benzinga.com
BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target
BTIG analyst Julian Harrison reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy and maintain
defenseworld.net
HB Wealth Management LLC Purchases New Position in Nektar Therapeutics $NKTR
HB Wealth Management LLC purchased a new stake in Nektar Therapeutics (NASDAQ: NKTR) in the second q
benzinga.com
BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target
BTIG analyst Julian Harrison reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy and maintain
benzinga.com
Nektar Therapeutics Announces Publication Of Peer-Reviewed Data From 16-Week Induction Period Of REZ
REZOLVE-AD study met all primary and key secondary endpoints, including EASI-75, EASI-90, Itch NRS,
benzinga.com
JP Morgan Reinstates Neutral on Nektar Therapeutics, Announces $65 Price Target
JP Morgan analyst Jessica Fye reinstates Nektar Therapeutics (NASDAQ:NKTR) with a Neutral and ann